

**FOR IMMEDIATE RELEASE**

## **Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India**

Mumbai, December 28, 2021: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's molnupiravir under the brand name Molxvir® in India. Earlier this year, Sun Pharma had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India.

The Drugs Controller General of India (DCGI), based on the review of clinical data of molnupiravir has approved molnupiravir for treatment of adult patients with Covid-19, with SpO<sub>2</sub> > 93% and who have high risk of progression of the disease including hospitalisation or death.

"Molnupiravir is an important addition to the portfolio of oral therapies available for treating Covid-19 patients," said Kirti Ganorkar, CEO of India Business, Sun Pharma. "In line with our consistent efforts to accelerate access to new drugs for Covid-19 treatment, we will make Molxvir® available to patients at an affordable price. We are also in the process of launching a toll-free helpline to ensure the availability of Molxvir® to doctors and patients across India. Our endeavour is to make the product available in a week's time."

The recommended dose of the drug is 800 mg twice a day for five days. The duration of treatment of molnupiravir is much shorter compared to other therapies which is a significant advantage as it reduces the pill burden and enhances compliance.

Molnupiravir has been developed by MSD and Ridgeback Biotherapeutics. It has been approved by the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Emergency Use Authorization (EUA).

Molxvir® is a registered trade mark of Sun Pharma.

### **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

**Sun Pharmaceutical Industries Limited**

SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R &D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) & follow us on [Twitter@SunPharma\\_Live](https://twitter.com/SunPharma_Live).

**Contacts:**

**Investors:**

Nimish Desai

Tel +91 22 4324 4324, Xtn 2778

Tel +91 22 4324 2778

Direct

Mobile +91-98203 30182

E mail [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

**Media:**

Gaurav Chugh

Tel +91 22 4324 4324, Xtn 5373

Tel +91 22 4324 5373

Direct

Mobile +91 98104 71414

E mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)